Pre-Tax Profit Margin (Quarterly)

Pre-Tax Profit Margin: Earnings before taxes as a portion of total revenue. Calculated as: Pre-Tax Income / Total Revenues

BridgeBio Pharma, Inc. (BBIO) had Pre-Tax Profit Margin of -63.97% for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$243.68M
Net Income	$-152.22M
Cost of Goods Sold	$15.05M
Gross Profit	$228.63M
Operating Expenses	$350.75M
Operating Income	$-107.08M
Non-Operating Income/Expense	$-48.81M
Pre-Tax Income	$-155.89M
Normalized Pre-Tax Income	$-155.89M
Income after Taxes	$-155.89M
Income from Continuous Operations	$-155.89M
Consolidated Net Income/Loss	$-155.89M
Normalized Income after Taxes	$-155.89M
EBIT	$-107.08M
EBITDA	$-104.10M
Weighted-Average Shares Outstanding (Basic)	195.79M
Weighted-Average Shares Outstanding (Diluted)	195.79M
Earnings per Share (EPS) (Basic)	$-0.78
Earnings per Share (EPS) (Diluted)	$-0.78
Balance Sheet Financials
Current Assets	$1.09B
Property, Plant, and Equipment	$5.23M
Long-Term Assets	$124.16M
Total Assets	$1.22B
Current Liabilities	$890.65M
Long-Term Debt	$1.93B
Long-Term Liabilities	$2.83B
Total Liabilities	$3.72B
Common Equity	$-2.50B
Tangible Shareholders Equity	$-2.53B
Shareholders Equity	$-2.50B
Common Shares Outstanding	195.28M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-268.38M
Cash Flow from Investing Activities	$-24.85M
Cash Flow from Financial Activities	$401.12M
Beginning Cash	$572.14M
End Cash	$680.04M
Increase/Decrease in Cash	$107.90M
Stock-Based Compensation	$77.31M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.23
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-3.34
Debt to Equity Ratio	-0.99
Gross Margin	93.83%
Operating Margin	-43.94%
EBIT Margin	-43.94%
EBITDA Margin	--
Pre-Tax Profit Margin	-63.97%
Profit Margin	-62.47%
Free Cash Flow	$-268.89M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.20
Inventory Turnover	0.28
Receiveable Turnover	0.96
Days Sales in Receivables	93.99
Return on Equity	6.22%
Return on Tangible Equity	6.16%
Return on Assets	-12.81%
Return on Investments	27.00%
Book Value Per Share	$-12.83
Free Cash Flow per Share	$-1.37
Operating Cash Flow per Share	$-1.37

Data from Zacks Investment Research, Inc.